Table 5 Effectiveness of implantable cardioverter defibrillators (ICDs) in clinical subgroups in latency 180 day* and latency 365 day* analyses

	Sample size (ICD/no ICD)	% of eligible patients received ICD	Event (ICD/no ICD)	IR† (ICD/no ICD)	Adjusted HR (95% CI)‡
					Latency 180 day	Latency 365 day
Outcome=death
Myocardial infarction:
Recent	1685/8160	17	565/4476	165/333	0.92 (0.77 to 1.09)	0.94 (0.76 to 1.16)
Old	448/904	33	186/648	226/532	0.63§ (0.45 to 0.86)	0.74 (0.51 to 1.08)
No	3125/8789	26	1108/5317	172/369	0.90 (0.79 to 1.03)	0.91 (0.78 to 1.07)
Left bundle branch block:
No	5143/17 406	23	1809/10 161	173/358	0.92 (0.83 to 1.01)	0.94 (0.83 to 1.06)
Yes	115/447	20	50/280	213/401	0.64 (0.34 to 1.17)	0.75 (0.37 to 1.49)
B type natriuretic peptide:
<800	1085/1604	40	359/905	157/302	0.86 (0.67 to 1.10)	0.86 (0.65 to 1.15)
≥800	1006/3439	23	490/2373	278/464	0.94 (0.78 to 1.13)	0.91 (0.72 to 1.13)
Outcome=sudden cardiac death
Myocardial infarction:
Recent	1685/8160	17	115/542	34/40	1.03 (0.76 to 1.39)	0.92 (0.64 to 1.33)
Old	448/904	33	27/83	33/68	0.74 (0.40 to 1.35)	1.12 (0.56 to 2.21)
No	3125/8789	26	188/701	29/49	0.91 (0.70 to 1.18)	1.00 (0.73 to 1.38)
Left bundle branch block:
No	5143/17 406	23	325/1289	31/45	0.97 (0.80 to 1.17)	1.02 (0.81 to 1.29)
Yes	115/447	20	5/37	21/53	0.51 (0.16 to 1.61)	0.42 (0.09 to 2.05)
B type natriuretic peptide:
<800	1085/1604	40	92/199	40/66	1.11 (0.69 to 1.77)	1.42 (0.82 to 2.46)
≥800	1006/3439	23	132/539	75/105	1.20 (0.85 to 1.69)	1.17 (0.76 to 1.80)

*Latency 180 day analyses: starting follow-up from 180 days after index time; latency 365 day analyses: starting follow-up from 365 days after index time.

†IR=incidence rate per 1000 person years.

‡Adjusted for high dimension propensity score.

§P<0.05.